This paper explores the disease burden indicated by GlycA, analyzing the risk for 468 common incident hospitalization and mortality outcomes during an 8-year follow-up of 11,861 adults in Finland.

Results replicated known associations and identified associations with specific cardiovascular disease outcomes, alcoholic liver disease, chronic renal failure, glomerular diseases, chronic obstructive pulmonary disease, inflammatory polyarthropathies and hypertension. GlycA was further evaluated as a biomarker in secondary prevention of 12-year cardiovascular mortality in 900 angiography patients with suspected coronary artery disease.